| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6159498 | BDSI | Bioerodable film for delivery of pharmaceutical compounds of mucosal surfaces |
Oct, 2016
(7 years ago) | |
| US7579019 | BDSI | Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces |
Jan, 2020
(4 years ago) | |
| US9655843 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
| US8147866 | BDSI | Transmucosal delivery devices with enhanced uptake |
Jul, 2027
(3 years from now) | |
| US9901539 | BDSI | Transmucosal drug delivery devices for use in chronic pain relief |
Dec, 2032
(8 years from now) | |
Belbuca is owned by Bdsi.
Belbuca contains Buprenorphine Hydrochloride.
Belbuca has a total of 5 drug patents out of which 2 drug patents have expired.
Expired drug patents of Belbuca are:
- US6159498
- US7579019
Belbuca was authorised for market use on 23 October, 2015.
Belbuca is available in film;buccal dosage forms.
Belbuca can be used as treatment of pain by transmucosal delivery of buprenorphine, management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
The generics of Belbuca are possible to be released after 21 December, 2032.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 23, 2018 |
Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 October, 2015
Treatment: Treatment of pain by transmucosal delivery of buprenorphine; Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options...
Dosage: FILM;BUCCAL
BELBUCA family patents
